Author

Christopher L. Carroll

Observed names: Carroll, Christopher L., Chris L. Carroll

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-7212-7268

Observed ORCID: 0000-0002-7212-7268

OpenAlex ID: A5044148124

Discovery of IPN60090, a Clinical Stage Selective Glutaminase‑1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

2020 · Michael J. Soth, Kang Le, et al. · Journal of Medicinal Chemistry · 107

Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers

2024 · Christopher L. Carroll, Michael G. Johnson, et al. · Journal of Medicinal Chemistry · 22

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

2024 · Patrick G. Pilié, Virginia Giuliani, et al. · Clinical Cancer Research · 21

Data from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

2024 · Patrick G. Pilié, Virginia Giuliani, et al.

Supplementary Table S1 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

2024 · Patrick G. Pilié, Virginia Giuliani, et al.

Supplementary S1-S8 from Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

2024 · Patrick G. Pilié, Virginia Giuliani, et al.

CCDC 2191608: Experimental Crystal Structure Determination

2022 · Czako, Barbara, Sun, Yuting, et al. · The Cambridge Structural Database

Works count: 7

Citation count: 150

H-index: 3

I10-index: 3